PMVP (PMV Pharmaceuticals) Beginning Cash Position: $37.98 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PMVP PMV Pharmaceuticals Inc PMVP
34 GF Score
Price $1.33
! 2 Warning Signs
View Full Analysis

What is PMV Pharmaceuticals Beginning Cash Position?

PMV Pharmaceuticals PMVP +3.47% 34 Beginning Cash Position is $37.98 Mil as of Mar. 2026. GuruFocus rates PMVP with a GF Score™ of 34/100. The stock has 2 warning signs investors should review.

PMV Pharmaceuticals's Beginning Cash Position for the quarter that ended in Mar. 2026 was $37.98 Mil.

PMV Pharmaceuticals's quarterly Beginning Cash Position declined from Sep. 2025 ($44.13 Mil) to Dec. 2025 ($36.34 Mil) but then increased from Dec. 2025 ($36.34 Mil) to Mar. 2026 ($37.98 Mil).

PMV Pharmaceuticals's annual Beginning Cash Position declined from Dec. 2023 ($109.12 Mil) to Dec. 2024 ($38.53 Mil) but then increased from Dec. 2024 ($38.53 Mil) to Dec. 2025 ($40.88 Mil).

PMV Pharmaceuticals Beginning Cash Position Related Terms

PMV Pharmaceuticals Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for PMV Pharmaceuticals's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PMV Pharmaceuticals Beginning Cash Position Chart

PMV Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial 361.42 173.29 109.12 38.53 40.88

PMV Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 40.88 51.34 44.13 36.34 37.98
PMVP
34GF Score
PMV Pharmaceuticals Inc PMVP
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PMV Pharmaceuticals Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $37.98 Mil mean?
PMV Pharmaceuticals (PMVP) has a Beginning Cash Position of $37.98 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on PMV Pharmaceuticals and its competitors.
Is PMV Pharmaceuticals' Beginning Cash Position too high?
PMV Pharmaceuticals' current Beginning Cash Position is $37.98 Mil. Overall, PMV Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does PMV Pharmaceuticals' Beginning Cash Position compare to MNOV and TCRX?
PMV Pharmaceuticals' Beginning Cash Position of $37.98 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on PMV Pharmaceuticals and its competitors. PMV Pharmaceuticals's current Beginning Cash Position is $37.98 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PMV Pharmaceuticals stock overvalued right now?
PMV Pharmaceuticals (PMVP) has a current Beginning Cash Position of $37.98 Mil. The current Beginning Cash Position is $37.98 Mil. PMV Pharmaceuticals' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For PMV Pharmaceuticals (PMVP), the current Beginning Cash Position is $37.98 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PMV Pharmaceuticals Business Description

Address 400 Alexander Park Drive, Suite 301, Princeton, NJ, USA, 08540
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.
34GF Score

Get the complete analysis for PMVP

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.33
Price